<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2258">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04447404</url>
  </required_header>
  <id_info>
    <org_study_id>C928-020</org_study_id>
    <nct_id>NCT04447404</nct_id>
  </id_info>
  <brief_title>DUR-928 in Subjects With SARS-CoV-2 With Acute Liver or Kidney Injury</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Safety and Efficacy of DUR-928 in Subjects Infected With SARS-CoV-2 With Acute Liver or Kidney Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Durect</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Durect</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate safety and efficacy of DUR-928 in treatment of acute organ failure in subjects
      infected with SARS-CoV-2
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>3:1 randomization DUR-928:placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite endpoint of alive and free of organ failure</measure>
    <time_frame>Day 28</time_frame>
    <description>Free of mechanical ventilation, free of renal replacement therapy and free of acute liver failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of serious adverse events following treatment</measure>
    <time_frame>Day 1 to Day 60</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alive at days 28 and 60</measure>
    <time_frame>Days 28 and 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alive and out of ICU</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alive and out of hospital</measure>
    <time_frame>Day 28 and Day 60</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>SARS-CoV 2</condition>
  <arm_group>
    <arm_group_label>DUR-928</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DUR-928</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>DUR-928</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized with moderate, severe, or early critical COVID-19 illness diagnosed by
             RT- PCR

          -  Acute liver injury (including acute on chronic liver disease) or acute kidney injury

        Exclusion Criteria:

          -  Critical COVID-19 illness (MAP &lt; 60 mm Hg, on mechanical ventilator for â‰¥ 5 days)

          -  On maintenance hemodialysis or peritoneal dialysis

          -  Child Pugh C cirrhosis

          -  Hepatorenal syndrome

          -  Ascites and/or hepatic encephalopathy

          -  History of end stage renal disease or CKD with eGFR &lt; 15 mL/min/1.73m2

          -  Women who are pregnant or breast feeding

          -  Receipt of other concomitant experimental therapies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Gordon, MD</last_name>
    <role>Study Director</role>
    <affiliation>CTI Clinical Trial &amp; Consulting Services</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deborah Scott</last_name>
    <phone>408-777-1417</phone>
    <email>deborah.scott@durect.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Fergus</last_name>
    <phone>408-777-1417</phone>
    <email>julie.fergus@durect.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site 02</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 01</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 03</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 23, 2020</study_first_submitted>
  <study_first_submitted_qc>June 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2020</study_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

